About: Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125 Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 May 1996

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в травні 1996 (uk) im Mai 1996 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu en mayu de 1996 (ast) scientific article published on 01 May 1996 (en)
publication date	wds:Q71059798-DB3968A5-4C28-493F-8386-5C59987F123B
publication date	1996-05-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q71059798-5A2DFF9A-9C0D-47BB-BEC7-AEA5DDD2646D
language of work or name	English
author name string	wds:Q71059798-1CF3C77D-B767-447A-8193-482D9BFE1E4F wds:Q71059798-640E52FF-F953-4333-959B-9277A61B7579 wds:Q71059798-646C7490-F373-4386-9F26-E264FD95AB01 wds:Q71059798-66F02C69-5AA4-464C-A02A-22123EF47916 wds:Q71059798-779F492A-A10B-4477-9AA5-7818AA5DFE95 wds:Q71059798-98A4CC21-001C-4810-BD02-71E6F34CAAE2 wds:Q71059798-B1A67F09-7C6F-450E-A79C-E3F69D3CA5CF wds:Q71059798-E7C35048-EBC3-4359-8EA8-70C6913568DB
author name string	G J Rustin W J Hoskins M F Brady W P McGuire H Mitchell H E Lambert P McClean A E Nelstrop
rdfs:label	Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125 (en) Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125 (nl)
skos:prefLabel	Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125 (en) Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125 (nl)
name	Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125 (en) Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125 (nl)
title	wds:Q71059798-D589E39E-9C57-4BC6-A792-B98BE458817A
title	Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125 (en)
page(s)	wds:Q71059798-3C73CD0A-B6D1-4BD3-8BD5-D48BC3C80FFA
page(s)	1545-1551
instance of	wds:Q71059798-E3FA611F-62A9-4F99-B7AD-71BC6CC733FD
instance of	scholarly article
main subject	wds:Q71059798-1F927CEB-BEF4-4F26-9230-1066A8AA14B5 wds:Q71059798-4A10EAB4-DB4F-49A7-909D-F52F5B6313A1 wds:Q71059798-DC8D1E33-70FF-4B1E-A587-42AB06E076C7
main subject	ovarian carcinoma Mucin 16, cell surface associated chemotherapy
PubMed ID	wds:Q71059798-B15B7695-08E5-4B35-81BE-F066F12155B0
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/8622070
PubMed ID	8622070
published in	wds:Q71059798-8466A171-FBEE-4CA5-999D-04AF2F585EC4
published in	Journal of Clinical Oncology
issue	wds:Q71059798-D98AABE1-EDDC-4C0D-B8B9-5570B9BC1F1B
volume	wds:Q71059798-6FD7648C-764C-4AD0-B349-DF25D60FDE92
issue	5
volume	14
DOI	wds:Q71059798-950D31EA-1834-4DF3-AF82-154CD98D7E04
DOI	http://dx.doi.org/10.1200/JCO.1996.14.5.1545
DOI	10.1200/JCO.1996.14.5.1545
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q71059798
is cites work of	Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer Polyethylene glycol-liposomal doxorubicin: a review of its use in the management of solid and haematological malignancies and AIDS-related Kaposi's sarcoma Plasma miRNAs as diagnostic and prognostic biomarkers for ovarian cancer Effects of blood collection conditions on ovarian cancer serum markers Neoadjuvant chemotherapy followed by surgery and adjuvant chemotherapy in patients with primarily unresectable, advanced-stage ovarian cancer. Sequential chemotherapy with carboplatin followed by weekly paclitaxel in advanced ovarian cancer: results of a multicenter phase II study of the northeastern German society of gynecological oncology A phase II trial of docetaxel in platinum pre-treated patients with advanced epithelial ovarian cancer: a Japanese cooperative study Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: results from the SOCRATES retrospective study. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary Comparison of clinical outcomes of patients with clear cell and endometrioid ovarian cancer associated with endometriosis to papillary serous carcinoma of the ovary Efficacy of taxane and platinum-based chemotherapy guided by extreme drug resistance assay in patients with epithelial ovarian cancer Eribulin mesylate (halichondrin B analog E7389) in platinum-resistant and platinum-sensitive ovarian cancer: a 2-cohort, phase 2 study A study to evaluate the use of CA125 in ovarian cancer follow-up: A change in practice led by patient preference A phase II trial of weekly paclitaxel and every 3 weeks of carboplatin in potentially platinum-sensitive ovarian and peritoneal carcinoma Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer: Updated Guidelines From the European Group on Tumor Markers Sequential prolonged oral topotecan and prolonged oral etoposide as second-line therapy in ovarian or peritoneal carcinoma: a phase I Gynecologic Oncology Group study Pharmaceutical management of ovarian cancer : current status An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer Pharmacoeconomic considerations in treating ovarian cancer Phase II trial of anastrozole in women with asymptomatic müllerian cancer Epithelial ovarian carcinoma Pegylated liposomal doxorubicin (Lipo-Dox) for platinum-resistant or refractory epithelial ovarian carcinoma: a Taiwanese gynecologic oncology group study with long-term follow-up Phase II trial of carboplatin and distearoylphosphatidylcholine pegylated liposomal doxorubicin (Lipo-Dox) in recurrent platinum-sensitive ovarian cancer following front-line therapy with paclitaxel and platinum CA-125 response in patients with recurrent ovarian or primary peritoneal cancer treated with pegylated liposomal doxorubicin or topotecan Current state of biomarker development for clinical application in epithelial ovarian cancer The effect of single weekly paclitaxel in heavily pretreated patients with recurrent or persistent advanced ovarian cancer. BCL2 antagonist of cell death kinases, phosphatases, and ovarian cancer sensitivity to cisplatin The lack of significance of Ca125 response in epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and delayed primary surgical debulking Phase II trial of Oxaliplatin and 5-Fluorouracil/Leucovorin combination in epithelial ovarian carcinoma relapsing within 2 years of platinum-based therapy Analysis of 96 patients with advanced ovarian carcinoma treated with high-dose chemotherapy and autologous stem cell transplantation Ovarian cancer Weekly topotecan for recurrent platinum resistant ovarian cancer Prevalence of epithelial ovarian cancer stem cells correlates with recurrence in early-stage ovarian cancer The safety and efficacy of the weekly dosing of irinotecan for platinum- and taxanes-resistant epithelial ovarian cancer Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma Imaging ovarian cancer and peritoneal metastases--current and emerging techniques The prognostic and predictive value of CA-125 regression during neoadjuvant chemotherapy for advanced ovarian or primary peritoneal carcinoma Estrogen-regulated gene expression predicts response to endocrine therapy in patients with ovarian cancer Role of tumour markers in monitoring epithelial ovarian cancer Correlation between CA-125 serum level and response by RECIST in a phase III recurrent ovarian cancer study High GOLPH3 expression is associated with a more aggressive behavior of epithelial ovarian carcinoma Outcome of ATP-based tumor chemosensitivity assay directed chemotherapy in heavily pre-treated recurrent ovarian carcinoma

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 180 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software